Why the study?
Does Celecoxib reduce preterm delivery rates in a mouse model of LPS-induced preterm delivery?
Does Celecoxib reduce preterm delivery rates in a mouse model of LPS-induced preterm delivery?
Celecoxib demonstrates tocolytic efficacy in a mouse model of preterm delivery but carries a risk of fetal ductus arteriosus constriction.
Answers are grounded in this paper and cite their sources.
Supports celecoxib tocolysis in murine preterm models; leaves open human translation pending fetal safety data.
The inflammatory process is known to cause preterm delivery. Recently, a cyclooxygenase (COX)-2 inhibitor has been developed as an anti-inflammatory drug with few side-effects. We evaluated the COX-2 inhibitor, Celecoxib, for its tocolytic effects and side-effects on dams and pups using a lipopolysaccharide (LPS)-induced preterm delivery mouse model (preterm delivery rates; 95%). With administration of Celecoxib (50, 10, 1 and 0.3 mg/kg), the preterm labour rate was significantly reduced to 18, 30, 36 and 60% respectively. The prostaglandin F(2alpha)(PGF(2alpha)) and PGE(2) concentrations in murine uterine tissue 4 and 10 h after LPS treatment with Celecoxib (10 and 1 mg/kg) were significantly lower than those in the LPS-treated group without CELECOXIB: With administration of 10 or 100 mg/kg Celecoxib, the fetal ductus arteriosus was constricted significantly in preterm and near-term rats, although constriction rates in preterm rats were significantly lower than those in near-term rats. Reproductive and renal functions in offspring whose mothers were treated with LPS and Celecoxib were normal. These data demonstrate that Celecoxib could be used as a new therapy for preterm labour. However, careful attention to constriction of the fetal ductus arteriosus should be given.
No takes yet. Share an insight, caveat, or question.
M. Sakai (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: